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Abstract
Background: This study was performed to better understand the genetic diversity of known polymorphisms in
pfatpase6 and pfmdr1 genes before the introduction of ACT in Brazil, in order to get a genotypic snapshot of
Plasmodium falciparum parasites that may be used as baseline reference for future studies.
Methods: Parasites from P. falciparum samples collected in 2002, 2004 and 2006-2007 were genotyped using PCR
and DNA sequencing at codons 86, 130, 184, 1034, 1042, 1109 and 1246 for pfmdr1 gene, and 243, 263, 402, 431,
623, 630, 639, 683, 716, 776, 769 and 771 for pfatpase6 gene.
Results: A pfmdr1 haplotype NEF/CDVY was found in 97% of the samples. In the case of pfatpase6, four
haplotypes, wild-type (37%), 630 S (35%), 402 V (5%) and double-mutant 630 S + 402 V (23%), were detected.
Conclusion: Although some polymorphism in pfmdr1 and pfatpase6 were verified, no reported haplotypes in both
genes that may mediate altered response to ACT was detected before the introduction of this therapy in Brazil.
Thus, the haplotypes herein described can be very useful as a baseline reference of P. falciparum populations
without ACT drug pressure.
Background
Resistance to anti-malarial drugs is one of the major
obstacles to effective malaria treatment and control. Due
to the worldwide spread of Plasmodium falciparum
resistant to chloroquine and sulphadoxine-pyrimetha-
mine, the World Health Organization (WHO) recom-
mends the use of artemisinin-based combination
therapy (ACT) as first-line malaria treatment. Artemisi-
nin and its derivatives rapidly reduce clinical symptoms
and parasite burden. Combination with a second agent
improves treatment outcomes and minimizes the possi-
bility of selecting artemisinin-resistant parasites [1].
ACT has demonstrated outstanding anti-malarial effi-
cacy, but its long-term promise has recently come into
question. First, P. falciparum f i e l di s o l a t e sf r o mF r e n c h
Guyana and Senegal with markedly reduced in vitro sen-
sitivity to artemether were reported [2], although other
reports from a number of areas have not replicated
these results [3-5]. Second, recent reports from Cambo-
dia identified parasites with slightly reduced in vitro sen-
sitivity, but also showed significant prolongation of
parasite clearance times after treatment with artesunate
[6,7]. These results lead to concern that parasites with
diminished sensitivity to artemisinins may be spreading
around the world.
The mechanism of decreased susceptibility of malaria
parasites to artemisinins is uncertain. Gene amplification
or specific point mutations in codons 86, 184, 1034,
1042 and 1246 of the P. falciparum multidrug resistance
gene 1 (pfmdr1), have been associated with alterations
in artemisinin sensitivity by genetic disruption, allelic
replacement and in vitro experiments [8-11]. These
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some other anti-malarials, including mefloquine and
lumefantrine, and also enhanced response to chloro-
quine and amodiaquine [8,12,13]. There are also some
indications for pfmdr1 in vivo allele selection [14-18],
mainly N86, 184F and D1246, in reinfecting parasites
after artemether-lumefantrine (AL) treatment, a fact that
may constitute a first step toward resistance [19].
A second gene in which polymorphisms may mediate
alterations in artemisinin sensitivity is that encoding a
SERCA-type calcium-translocating ATPase known as pfat-
pase6 [2], the only ATPase identified in the P. falciparum
genome. However, this gene is more diverse than pre-
viously thought [20] and evidence of the roles of pfatpase6
mutations, specially that at codon S769N, in decreased
in vitro sensitivity to artemisinins is uncertain [21].
To better understand this diversity and to get a geno-
typic snapshot baseline for future studies, known poly-
morphisms in pfatpase6 and pfmdr1 genes were
assessed in P. falciparum parasites before the introduc-
tion of ACT in Brazil. At that time, treatment regimen
recommended to falciparum malaria by Malaria
National Control Program (MNCP) was quinine plus
doxycycline or mefloquine. From 2007, Brazilian MNCP
has been implementing ACT (artemether-lumefantrine
and artesunate-mefloquine) as first-line regimen for
uncomplicated falciparum malaria.
In Brazil, genotyping of pfmdr1 gene is scarce and
pfatpase6 analysis has just started. Two of such studies,
conducted in 1998, evaluated polymorphisms on pfmdr1
gene [22,23] and the recent investigation of pfatpase6
gene mutations was carried out with P. falciparum para-
sites from a single Pará state locality where only 14% of
the isolates studied were DNA sequenced [4].
Methods
Study sites, blood samples and DNA extraction
Parasites from 119 P. falciparum blood samples were
evaluated. These samples were collected in different per-
iods, at the time of diagnosis of uncomplicated falci-
parum malaria patients living in three Brazilian endemic
areas: Porto Velho, Rondônia state (2002; n = 46); Para-
gominas, Pará state (2004; n = 19); and Manaus, Amazo-
nas state (2006-2007; n = 54). Irrespective the locality,
the casuistic comprised male young adults (mean age 30
years) with 1900 parasites/μL mean parasitaemia, that
reported at least three previous malaria episodes. After
obtaining informed consent, venous blood was collected
according to protocols approved by the ethics research
committees of Fiocruz, Fundação de Medicina Tropical
do Amazonas, Instituto Evandro Chagas and Laboratory
of Entomology. Pregnant women, indigenous people,
prisoners and individualsl e s st h a n1 8y e a r so fa g e
were excluded. DNA was extracted from 1 ml of
cryopreserved blood using QIAamp midi columns as
described by the manufacturer (Qiagen).
Characterization of polymorphisms
Relevant portions of the pfmdr1 and pfatpase6 genes
were amplified using primers as previously described to
amplify N86Y, E130K, Y184F, S1034C, N1042 D,
V1109I and D1246Y pfmdr1 SNPs [24] and H243Y,
L263E, L402V, E431K, A623E, A630 S, G639 D, N683K,
K716R, K776N, S769N plus K771E pfatpase6 SNPs [25].
PCR products were separated by 2% agarose-gel electro-
phoresis. Products were purified through the Wizard SV
Gel and PCR Clean-Up System (Promega), according to
the manufacturer’s instructions. Amplified fragments
were directly sequenced using Big Dye® Terminator
Cycle Sequencing Ready Reaction version 3.1 (Applied
Biosystems) on an ABI PRISM DNA Analyzer 3730
(Applied Biosystems) from the Genomic Platform/
PDTIS/Fiocruz [26].
Results
Only isolates that were successfully amplified at all
regions of a gene were considered. In this light, pfmdr1
polymorphisms were evaluable in 85 samples (19 for
Paragominas, 33 for Porto Velho and 33 for Manaus
localities) and pfatpase6 polymorphisms in 65 samples
(17 for Paragominas, 22 for Porto Velho and 26 for
Manaus) for the most likely haplotype assembly. The
amplification failures might have been due to primer
sensitivity or to unexpected polymorphisms in target
sequences, since all these samples generated DNA frag-
ments using primers employed in malaria diagnosis
based in conserved DNA regions [27]. Unsuccessfully
PCR amplifications were already reported to pfmdr1
gene [28] and in relation to pfatpase6 gene at least 25%
of the samples did not have evaluable SNPs [29].
Analysis of pfmdr1 gene revealed four single haplo-
types. Three of these contained SNPs already associated
with altered sensitivity to anti-malarial drugs (86Y, 184F,
1034C, 1042 D and 1246Y). One pfmdr1 haplotype NEF/
CDVY (N86, E130, 184F, 1034C, 1042 D, V1109 and
1246Y) was present in 97% of samples. One parasite
from Manaus displayed a wild type (3D7 strain) profile
(Table 1). Concerning the pfatpase6 gene, four single
haplotypes were found (HLLE/AAGNKKSK in 37% of
samples, HLLE/ASGNKKSK in 35%, HLVE/AAGNKKSK
in 5% and HLVE/ASGNKKSK in 23% of samples), dis-
playing none, one (402 V or 630S) or two (402 V plus
630S) SNPs within the 12 positions analysed (H243Y,
L263E, L402V, E431K, A623E, A630 S, G639 D, N683K,
K716R, K776N, S769N and K771E). Mixed haplotypes
were not seen in any samples.
A multilocus analysis was performed for 65 samples for
which both pfmdr1 and pfatpase6 were evaluable. The
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of haplotypes): NEF/CDVY + HLLE/ASGNKKSK
(41%), NEF/CDVY + HLLE/AAGNKKSK (31%), NEF/
CDVY + HLVE/ASGNKKSK (25%), NEF/CDVY +
HLVE/AAGNKKSK (1.5%) and YEY/SNVD + HLLE/
AAGNKKSK (1.5%).
Of the three studied localities, Paragominas and Porto
Velho displayed only one pfmdr1 haplotype (NEF/
CDVY), in contrast to Manaus, which presented some
allelic variation (NEF/CDVY, NEY/SNVD, YEY/SNVD
and NEF/SDVY). However, even in Manaus, NEF/CDVY
was by far the most prevalent haplotype (91%). For pfat-
pase6, HLLE/ASGNKKSK was predominant in Parago-
minas (65%), HLVE/ASGNKKSK in Porto Velho (68%),
and HLLE/AAGNKKSK and HLLE/ASGNKKSK haplo-
types in Manaus (54% and 46%, respectively).
Discussion
It was assessed mutations in two genes of P. falciparum
parasites that have previously been implicated in med-
iating resistance to artemisinin and other anti-malarial
drugs, from Rondônia, Pará and Amazonas states in
Brazil. It was found a range of polymorphisms in both
pfmdr1 and pfatpase6, although pfmdr1 gene was more
polymorphic than pfatpase6 one.
Regarding pfmdr1, the majority of isolates from all sites
displayed the NEF/CDVY allele that was first described
in 1998 in P. falciparum isolates from Mato Grosso and
Amapá states [22,23]. The NEF/CDVY haplotype might
have been selected by extensive use of quinine in Brazil,
as suggested by a reverse genetics experiment in which
mutations 1034C + 1042 D + 1246Y were associated with
decreased sensitivity to quinine [12]. In Manaus city,
another haplotype, YEY/SNVD, was seen in one sample.
This haplotype has previously been reported in Colombia
and Guyana [30,31], but not in Brazil. The set of pfmdr1
haplotypes herein identified did not include the combina-
tion of N86, 184F and D1246 codons, already reported in
patients with recurrent parasitaemia after AL treatment
[14-18].
For pfatpase6 a few polymorphisms were detected as
already observed in another Pará state locality [4], con-
trasting to those reported in Africa [15]. Importantly,
the S769N mutation, which was previously reported to
associate with decreased in vitro response to artemether
in French Guiana, was not seen. In 35% of the isolates,
only one SNP (630S) was detected in parasites from
Paragominas and Manaus, and double-mutant parasites
(402V + 630S) were noticed in 23% of the isolates, in
parasites from Porto Velho. The 402V and 630 S muta-
tions have also been detected in P. falciparum parasites
from Africa [20,25,32] and elsewhere [33], but they were
not observed in another study of Brazilian isolates from
Tucuruí city, Pará state [4]. It is noteworthy that para-
sites from Paragominas, a rural and isolated locality, had
the 630 S mutation, demonstrating that polymorphisms
have a broad geographical range.
After an initial report linking a pfatpase6 polymorph-
ism with altered response to artemether [2], the associa-
tion between pfatpase6 SNPs and artemisinin response
has been uncertain. Recent in vivo reports did not find
associations between altered artemisinin responses and
pfatpase6 polymorphisms [6,7,34]. Further, parasites
selected for artemisinin tolerance did not contain pfat-
pase6 SNPs previously associated with altered artemisinin
response [35]. Thus, the role of pfatpase6 polymorphisms
is uncertain, but in any event a range of polymorphisms
in both this gene and in pfmdr1 was observed in Brazil.
Conclusions
In this study, although some polymorphism in pfmdr1
and pfatpase6 were verified, no reported haplotypes in
both genes that may mediate altered response to ACT
were detected before the introduction of this therapy in
Brazil. Thus, the haplotypes herein described can be
very useful as baseline reference of P. falciparum popu-
lations without ACT drug pressure.
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Table 1 Pfmdr1 and pfatpase6 haplotypes from
Paragominas (PRG), Porto Velho (PV) and Manaus (MAN)
isolates.




NEF/CDVY 82 (19/PRG, 33/PV, 30/
MAN)
97 4
NEF/SDVY 1 (MAN) 1 3
YEY/SNVD 1 (MAN) 1 1










23 (11/PRG, 12/MAN) 35 1
HLVE/
AAGNKKSK
3 (PV) 5 1
HLVE/
ASGNKKSK
15 (PV) 23 2
Codon positions: pfmdr1 N86Y, E130K, Y184F, S1034C, N1042 D, V1109I,
D1246Y (n = 85); pftapase6 H243Y, L263E, L402V, E431K, A623E, A630 S, G639
D, N683K, K716R, K776N, S769N, K771E (n = 65). The haplotype of 3D7 strain
is underlined and the mutated codons are shown in bold characters.
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